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Previously we have shown that it is possible to target retroviral vectors to cells using avian sarcoma and leukosis virus
(ASLV) receptor–ligand and receptor–single-chain antibody bridge proteins (now designated as GATEs for guided adaptors
for targeted entry). In this report we were interested in determining whether this approach can be used to deliver retroviral
vectors specifically to cells that express heregulin receptors. Heregulin receptors are attractive targets for retroviral
vector-based gene delivery protocols since they are often overexpressed on the surfaces of cancer cells. To explore this
possibility, the TVA–herb1 protein was generated, consisting of the extracellular domain of the TVA receptor for ASLV-A fused
to the EGF-like region of heregulin b1. TVA–herb1 bound specifically to cells that express heregulin receptors, rendering them
susceptible to efficient and specific infection by subgroup A ASLV vectors. In addition, these activities of TVA–herb1 were
abrogated specifically in the presence of another bridge protein that contained the same ligand domain. These data confirm
that the GATE protein TVA–herb1 mediates targeted retroviral infection via cell surface heregulin receptors. © 2002 Elsevier
Science
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The ability to target viral vectors carrying therapeutic
or suicide genes to specific cell types would be of great
use in gene therapy of cancers. Retroviruses such as
avian sarcoma and leukosis viruses (ASLVs) or murine
leukemia viruses (MLVs) are advantageous in this regard
since they infect and predominantly establish proviral
DNA in actively dividing cells. The most common ap-
proach toward retargeting of viral vectors has been to
modify retroviral envelope (Env) proteins to contain a
ligand or a single-chain antibody (scAb) that bind a
particular cell surface marker (Chadwick et al., 1999;
Hatziioannou et al., 1999; Jiang et al., 1998, 1999; Kasa-
hara et al., 1994; Konishi et al., 1998; Martin et al., 1999;
Nilson et al., 1996; Peng et al., 1999; and reviewed in
Verma and Somia, 1997; Cosset and Russell, 1996). Al-
ternatively, retroviral targeting has been attempted using
molecular bridges consisting of a retroviral Env-specific
antibody that is crosslinked to either a ligand or to
another antibody that binds a specific cell surface
marker (Goud et al., 1988, Etienne-Julan et al., 1992; Roux
et al., 1989). However, difficulties with production of viral
particles containing modified Env proteins and a block to
virus cell membrane fusion have limited the progress of
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150these methods (Zhao et al., 1999; Verma and Somia,
1997; Cosset and Russell, 1996).
Recently, we and our collaborators were able to direct
ALV- and MLV-based retroviral vectors to specific cell
types using ASLV receptor–ligand and ASLV receptor–
single-chain antibody bridge proteins (Boerger et al.,
1999; Snitkovsky et al., 2000, 2001; Snitkovsky and Young,
1998). These bridge proteins contain the extracellular
domains of either the TVA or TVB receptors for sub-
groups A and B ASLV (ASLV-A and ASLV-B), respectively.
The bridge proteins that have been tested to date have
the ASLV receptor domains fused in-frame with epider-
mal growth factor (EGF), vascular endothelial growth
factor (VEGF), or a single-chain antibody (MR1) that
binds to a tumor-specific form of the EGF receptor. These
bridge proteins efficiently targeted the entry of retroviral
vectors to cells that express the cognate cellular recep-
tors (Snitkovsky and Young, 1998; Boerger et al., 1999;
Snitkovsky et al., 2000, 2001).
In this report, we have tested whether this approach
for retroviral targeting can be used to direct viral infection
toward cells that express heregulin receptors. The
heregulin receptors erbB2, erbB3, and erbB4 belong to a
family of class I tyrosine kinases that includes EGFR
(also designated as erbB1) (Carraway and Cantley, 1994;
Plowman et al., 1990, 1993). Homodimers of erbB3 and
erbB4 can serve as heregulin receptors (Tzahar et al.,
1994) and erbB2 binds heregulins only when it forms a
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Sliwkowski et al., 1994).
Heregulin receptors are relevant cell surface targets
for a retroviral targeting approach since ErbB2 is often
overexpressed in various malignancies, including breast
and ovarian carcinomas (Slamon et al., 1989), and clini-
cal studies have correlated overexpression of erbB2 in
female breast cancers with resistance to hormone ther-
apy, recurrence after surgery and radiation, and poor
survival (Giovanella et al., 1991; Ross and Fletcher, 1999;
Slamon et al., 1987, 1989). Also, heterodimers of erbB2
and erbB3 are expressed in a variety of tumor-derived
cells where they serve as high-affinity binding sites for
heregulins (Sliwkowski et al., 1994; Tzahar et al., 1994).
Heregulin b1 is one of the multiple heregulin isoforms
resulting from alternative splicing of a single gene
(Holmes et al., 1992; Wen et al., 1992). The EGF-like
domains of heregulins are sufficient for binding to
heregulin receptors and for mediating mitogenic signal-
ing (Holmes et al., 1992; Carraway et al., 1995). Among all
heregulin isoforms, the EGF-like domain of heregulin b1
has the highest affinity for these heterodimeric receptors
(Tzahar et al., 1994). Here we show that a TVA–heregulin
b1 bridge protein (TVA–herb1) that contains this EGF-like
domain specifically directs ASLV-A vector infection to
cells expressing the ErbB2 and ErbB3 heregulin recep-
tors.
RESULTS
TVA–herb1 binds specifically to N234 cells
A synthetic gene encoding TVA–herb1 was con-
structed as described under Materials and Methods.
TVA–herb1 consists of the extracellular domain of TVA
fused via a proline-rich linker region to the N-terminus of
the EGF-like domain of heregulin b1. TVA–herb1 was
produced as a secreted protein in the extracellular su-
pernatant of transiently transfected 293 cells and its
expression was confirmed by immunoblotting. TVA–
herb1 migrated as a heterogeneous protein species
ranging from 32 to 43 kDa (Fig. 1A), most probably
because its TVA domain is extensively modified post-
translationally (Bates et al., 1993).
TVA–herb1 was tested for its cell-specific binding
properties using NIH3T3 cells that lack heregulin recep-
tors (Carraway et al., 1995) and transfected NIH3T3 cells
(N234 cells) that express the erbB2/erbB3 heregulin re-
ceptors (Carraway et al., 1995). The cells were incubated
with extracellular supernatant that either lacked or con-
tained TVA–herb1 and the bound bridge protein was
detected using a previously described flow cytometry-
based assay that employs SUA–rIgG, a soluble subgroup
A ASLV SU–immunoglobulin fusion protein (Snitkovsky et
al., 1998, 2000, 2001). TVA–herb1 bound to N234 cells in
a concentration-dependent manner (Fig. 1B), whereas it
did not bind at all to NIH3T3 cells even when the maxi-mal amount of bridge protein was added (Fig. 1C). These
studies clearly show that TVA–herb1 binds specifically to
cells that express heregulin receptors. In addition, since
the cell surface-associated bridge protein was detected
by binding to SUA–rIgG, these studies confirm that the
bound protein is capable of interacting directly with sub-
group A ASLV Env.
TVA–herb1 mediates efficient and specific viral entry
into N234 cells
To determine whether TVA–herb1 can mediate infec-
tion by ASLV-A vectors into cells that express heregulin
receptors, N234 cells were incubated with increasing
amounts of this bridge protein prior to challenge with
RCASBP(A)–EGFP, a subgroup A ASLV vector encoding
the enhanced green fluorescent protein (EGFP) (Snit-
FIG. 1. TVA–herb1 binds specifically to N234 cells that express
heregulin receptors. (A) Expression of TVA–herb1. An aliquot of extra-
cellular supernatant containing TVA–herb1 was subjected to SDS–
PAGE under nonreducing conditions and then to immunoblotting using
a subgroup A ASLV SU–immunoglobulin fusion protein (SUA–rIgG) and
a horseradish peroxidase-conjugated secondary antibody as de-
scribed previously (Snitkovsky and Young, 1998). Molecular weight
markers are shown in kilodaltons. (B) TVA–herb1 binds to N234 cells.
N234 cells were incubated with supernatants that contained an in-
creasing amount of TVA–herb1 and the bound bridge protein was then
detected by flow cytometry using SUA–rIgG and a FITC-conjugated
secondary antibody as described previously (Snitkovsky and Young,
1998). (C) TVA–herb1 does not bind to NIH3T3 cells. NIH3T3 cells were
incubated with 500 ml extracellular supernatants that either lacked (2)
or contained (1) TVA–herb1 and the bound bridge protein was de-
tected by flow cytometry as described for B.kovsky et al., 2000, 2001). Infected cells were identified by
flow cytometry to detect EGFP expression. These studies
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tion of N234 cells in a concentration-dependent manner
(Fig. 2). To estimate the relative efficiency of TVA–herb1-
mediated infection of N234 cells compared with that
mediated by the transmembrane TVA receptor, NIH3T3–
TVAsyn cells were also challenged with virus. These cells
were derived from NIH3T3 cells by transduction with an
MLV vector that encodes an epitope-tagged form of the
transmembrane TVA receptor (Snitkovsky, 2000, 2001).
These studies showed that TVA–herb1-mediated infec-
tion was quite efficient since it led to viral transduction at
a level that was approximately 5% of that seen with cells
expressing the transmembrane receptor (Table 1). By
contrast to the results obtained with N234 cells, TVA–
herb1 failed to render the parental NIH3T3 cells suscep-
tible to viral infection (Table 1).
FIG. 2. TVA–herb1 mediates infection by a subgroup A ASLV vector
in a dose-dependent manner. N234 cells were incubated with extra-
cellular supernatant containing increasing amounts of TVA–herb1. The
cells were then washed and challenged with a 5-ml aliquot of a (1003
concentrated) stock of the RCASBP(A)–EGFP viral vector (Snitkovsky et
al., 2000, 2001). The number of virus-transduced cells was then deter-
mined by flow cytometry.
TABLE 1
TVA–herb1 Mediates Specific and Efficient
Viral Entry into N234 Cells
Cell type
Efficiency of ASLV-A infection (%)
2TVA–herb1 1TVA–herb1
NIH3T3 0.07 0.05
N234 0.11 5.04
NIH3T3–TVAsyn 100 N.D.
Note. NIH3T3 cells and N234 cells were incubated with or without
TVA–herb1 before challenge with the subgroup A ASLV vector RCASB-
P(A)–EGFP encoding the enhanced green fluorescent protein. The
relative numbers of EGFP-transduced cells were determined by flow
cytometric analysis and are shown compared with the number ob-
tained when the same amount of virus was used to infect NIH3T3–
syn 6TVA cells [9.6 3 10 EGFP-transducing units/ml (100-fold) concen-
trated virus, defined here as 100% infection]. N.D., not determined.TVA–herb1-mediated viral entry requires its binding
to cell surface heregulin receptors
To confirm that TVA–herb1-mediated viral entry re-
quires its binding to heregulin receptors expressed at
the surface of N234 cells, we attempted to compete
these activities of the bridge protein with two other
bridge proteins, TVBS3–herb1 and TVBS3–VEGF110 (Snit-
kovsky, 2001). These two bridge proteins consist of the
extracellular domain of the TVBS3 receptor for subgroups
B and D ASLV fused via a proline-rich linker region to
either the EGF-like region of heregulinb1 or a 110-amino-
acid form of VEGF (Snitkovsky et al., 2001). Expression of
each of these two proteins in the extracellular superna-
tant of transiently transfected human 293 cells was quan-
tified previously (Snitkovsky, 2001). TVBS3–herb1 blocked
the binding of TVA–herb1 to N234 cells (Fig. 3A) and
severely reduced the level of TVA–herb1-mediated viral
FIG. 3. TVA–herb1 mediates viral entry into N234 cells by binding to
heregulin receptors. (A) TVA–herb1 binding to N234 cells is blocked in
the presence of a heterologous bridge protein (TVBS3–herb1) that also
contains the heregulin b1 domain. N234 cells were incubated with
extracellular supernatant that either contained (1) or lacked (2) TVBS3–
herb1 or TVBS3–VEGF110 prior to incubation with TVA–herb1. The
bound TVA–herb1 protein was detected by flow cytometry as described
for Fig. 1B. (B) TVBS3–herb1 blocks TVA–herb1-dependent viral entry
into N234 cells. N234 cells were incubated with bridge proteins as
described for A and after washing they were challenged with the
RCASBP(A)–EGFP virus and virus infection was monitored as de-
scribed in the legend to Fig. 2.infection that was observed with these cells (Fig. 3B). By
contrast, preincubating N234 cells with TVBS3–VEGF110
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entry (Fig. 3B). Taken together, these studies confirm that
TVA–herb1 binds to heregulin receptors expressed at
the surface of N234 cells and demonstrate that this
interaction is required for bridge protein-mediated viral
entry.
DISCUSSION
In this report we have demonstrated that it is possible
to target retroviral infection specifically toward cells that
express heregulin receptors using a TVA–heregulin
bridge protein (TVA–herb1). Specifically we showed that
this bridge protein binds to transfected NIH3T3 cells that
express heregulin receptors (N234 cells) and that its
binding was specifically abrogated by a heterologous
bridge protein (TVBS3–herb1) that binds the same recep-
tor. Furthermore, TVA–herb1 rendered N234 cells sus-
ceptible to infection by a subgroup A ASLV vector in a
concentration-dependent manner, and this activity was
also inhibited by prior incubation of the cells with TVBS3–
herb1. The ability to target retroviral vectors via cell
surface heregulin receptors is an important first step for
the development of future gene therapy efforts that are
aimed at eliminating tumors that overexpress this type of
receptor.
The efficiency of TVA–herb1-mediated viral entry was
approximately 5% of that level seen with modified
NIH3T3 cells that express the transmembrane TVA re-
ceptor. This level of targeted viral entry compares favor-
ably with the previous data obtained when similar exper-
iments were performed with other bridge proteins that
target retroviral infection through wild-type EGF recep-
tors (6.6%; Snitkovsky, 1998), through VEGFR-2 (8.72%;
Snitkovsky, 2001), and through a tumor-specific form of
the EGF receptor, EGFRvIII (8.4%; Snitkovsky, 2000).
Therefore, this approach seems to give consistent re-
sults with several different receptor–ligand pairs.
ASLV receptor–ligand and ASLV receptor–single-chain
antibody bridge proteins direct retroviral infection toward
specific cell surface receptors. Therefore, we now des-
ignate these proteins collectively as GATEs (guided
adaptors for targeted entry). The use of GATE proteins is
not limited to targeting only ASLV or MLV vectors since it
can, in principle, be applied to any virus vector system
that can incorporate ASLV Env proteins. Furthermore,
recent studies have demonstrated that a similar ap-
proach results in adenovirus vector targeting using cox-
sackie B virus and adenovirus receptor (CAR)–EGF and
CAR–Fc bridge proteins (Dmitriev et al., 2000; Ebbing-
haus et al., 2001). The versatility of bridge proteins in
targeting different classes of viruses to cell types ex-
pressing different kinds of receptors may in the future
permit successful gene therapy in humans.MATERIALS AND METHODS
Cell lines
NIH3T3 cells were grown in DMEM containing 5%
FBS, L-glutamine, and penicillin/streptomycin (DMEM).
N234 cells were derived from NIH3T3 cells by transfec-
tion of ErbB2 and ErbB3 (a generous gift of K. Carraway)
and were grown in DMEM containing 800 mg/ml gene-
ticin (G418) (Gibco/BRL). NIH3T3 cells expressing TVAsyn
(NIH3T3–TVAsyn) were generated by infecting NIH3T3
cells with an MLV vector encoding TVAsyn, pseudotyped
with the VSV-G protein as described previously (Snit-
kovsky et al., 2000, 2001).
Generation of the TVA–heregulin b1 fusion protein
A synthetic gene encoding a proline-rich linker (Snit-
kovsky and Young, 1998) fused to the N-terminus of the
68 amino acids of the EGF-like domain of heregulin b1
(Holmes et al., 1992) was obtained by a PCR amplifica-
tion method (Soderlind et al., 1995) using six overlapping
complementary oligonucleotide primers that span the
sequence of the EGF-like domain of heregulin b1. The
primers used (arranged in order from the 59-end of the
synthetic gene) were sense primer #1 (59-gcgcggccgc-
ccaccacctgaactcctagggggaccggggaccagccaccttgtga-
aatg-39) with the EagI cloning site and the codons
encoding the proline-rich hinge region underlined; an-
tisense primer #2 (59-ctcgccgccgttcacgcagaaagttt-
tctccttctccgcacatttcacaaggtggctggtccccgg-39); sense
primer #3 (59-ctttctgcgtgaacggcggcgagtgcttcatgg-
ttaaagacctgtccaacccctcgcgctacttgtgcaagtgccca-
aatgagttcaccggcgatcgctgccaaaactacgtaatggcct-39);
antisense primer #4 (59-ggcagcgatcgccggtgaactcattt-
gggcacttgcacaagtagcgcgaggggttggacagg-39); sense
primer #5 (59-gagttcaccggcgatcgctgccaaaac-
tacgtaatggcctccttctacaagcacctggggatcg-39); and anti-
sense primer #6 (59-gcgcggccgggtaccttactcctccgc-
ctccataaattcgatccccaggtgcttgtagaagg-39) with the
EagI cloning site underlined. In brief, 30 pmol of prim-
ers #1 and #6 was mixed with 0.3 pmol of primers #2,
#3, #4, and #5 in a standard PCR amplification reac-
tion. The resultant 259-base-pair-long DNA fragment
was digested with EagI restriction enzyme and used to
replace the corresponding proline-rich and ligand re-
gions of TVA–EGF (Snitkovsky and Young, 1998) gen-
erating a plasmid expression vector encoding TVA–
herb1.
The TVA–herb1 protein, as well as the previously de-
scribed TVBS3–herb1 and TVBS3–VEGF110 proteins (Snit-
kovsky et al., 2001), was expressed in the extracellular
supernatants of transiently transfected human 293 cells
as previously described (Snitkovsky and Young, 1998).
Expression of TVA–herb1 was confirmed by subjecting
45 ml of the extracellular supernatant to electrophoresis
on a 10% polyacrylamide gel containing SDS. The protein
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detected by immunoblotting using an ALV-A surface (SU)
Env–rabbit IgG fusion protein (SUA–rIgG) as described
previously (Snitkovsky, 2000).
TVA–herb1 binding studies
Approximately 3.5 3 105 cells were detached from
tissue culture plates with Ca21/Mg21-free PBS containing
1 mM EDTA and placed on ice. N234 cells were incu-
bated at 4°C for 1 h with increasing amounts (up to 500
ml) of the extracellular supernatant taken from TVA–
herb1-expressing cells with each sample made up to a
total volume of 500 ml with a control supernatant taken
from nontransfected human 293 cells. NIH3T3 cells were
incubated with 500 ml of the control or TVA–herb1-con-
taining supernatants. The cells were then washed and
subjected to a flow cytometry assay using SUA–rIgG to
detect the bound bridge protein as described previously
(Snitkovsky, 2000). Competition binding studies were
performed in the same way except that the N234 cells
were preincubated for 1 h at 4°C with 490 ml of a control
supernatant or with extracellular supernatants that con-
tained TVBS3–herb1 or TVBS3–VEGF110 before the addi-
tion of a 10-ml sample of supernatant taken from TVA–
herb1-expressing cells.
Viral infection
All of the experiments described in this section were
performed at least three times each in triplicate. Approx-
imately 105 N234, NIH3T3, and NIH3T3–TVAsyn cells were
incubated for 1 h at 4°C with 500 ml of a control super-
natant taken from nontransfected human 293 cells. The
NIH3T3 cells were also incubated under the same con-
ditions with 500 ml of a supernatant taken from TVA–
herb1-expressing cells. N234 cells were also incubated
under the same conditions with increasing amounts of
the TVA–herb1-containing supernatant and in each case
the samples were made up to a total volume of 500 ml
with the control supernatant. The cells were then
washed and challenged with RCASBP(A)–EGFP, and the
infected cells were identified by flow cytometry as de-
scribed previously (Snitkovsky, 2000). The competition
experiments were performed in the same way except
that N234 cells were preincubated at 4°C for 30 min with
490 ml of the control supernatant or instead with 490 ml
of the supernatants containing TVBS3–herb1 or TVBS3–
VEGF110 before addition of 10 ml of the TVA–herb1-
containing supernatant.
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